Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment

被引:249
作者
Konradi, C
Heckers, S
机构
[1] McLean Hosp, Charles D Baker Lab Neuroplast, Mailman Res Ctr, Belmont, MA 02478 USA
[2] Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA 02129 USA
[3] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA
关键词
schizophrenia; glutamate; neuroplasticity; neurotoxicity; antipsychotic drugs; neuropathology;
D O I
10.1016/S0163-7258(02)00328-5
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The glutamate system is involved in many aspects of neuronal synaptic strength and function during development and throughout life. Synapse formation in early brain development, synapse maintenance, and synaptic plasticity are all influenced by the glutamate system. The number of neurons and the number of their connections are determined by the activity of the glutamate system and its receptors. Malfunctions of the glutamate system affect neuroplasticity and can cause neuronal toxicity. In schizophrenia, many glutamate-regulated processes seem to be perturbed. Abnormal neuronal development, abnormal synaptic plasticity, and neurodegeneration have been proposed to be causal or contributing factors in schizophrenia. Interestingly, it seems that the glutamate system is dysregulated and that N-methyl-D-aspartate receptors operate at reduced activity. Here we discuss how the molecular aspects of glutamate malfunction can explain some of the neuropathology observed in schizophrenia, and how the available treatment intervenes through the glutamate system. (C) 2002 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:153 / 179
页数:27
相关论文
共 373 条
[61]  
Coughenour LL, 1997, J PHARMACOL EXP THER, V280, P584
[62]  
Counihan TJ, 1998, J COMP NEUROL, V390, P91
[63]   The glutamatergic dysfunction hypothesis for schizophrenia [J].
Coyle, JT .
HARVARD REVIEW OF PSYCHIATRY, 1996, 3 (05) :241-253
[64]   DOPAMINE RECEPTOR-BINDING PREDICTS CLINICAL AND PHARMACOLOGICAL POTENCIES OF ANTI-SCHIZOPHRENIC DRUGS [J].
CREESE, I ;
BURT, DR ;
SNYDER, SH .
SCIENCE, 1976, 192 (4238) :481-483
[65]   Comparative analysis of group II metabotropic glutamate receptor immunoreactivity in Brodmann's area 46 of the dorsolateral prefrontal cortex from patients with schizophrenia and normal subjects [J].
Crook, JM ;
Akil, M ;
Law, BCW ;
Hyde, TM ;
Kleinman, JE .
MOLECULAR PSYCHIATRY, 2002, 7 (02) :157-164
[66]   THE NMDA POSITIVE MODULATOR D-CYCLOSERINE POTENTIATES THE NEUROLEPTIC ACTIVITY OF D1-DOPAMINE AND D2-DOPAMINE RECEPTOR BLOCKERS IN THE RAT [J].
DALLOLIO, R ;
GANDOLFI, O .
PSYCHOPHARMACOLOGY, 1993, 110 (1-2) :165-168
[67]   ACTIONS OF CLOZAPINE AND HALOPERIDOL ON THE EXTRACELLULAR LEVELS OF EXCITATORY AMINO-ACIDS IN THE PREFRONTAL CORTEX AND STRIATUM OF CONSCIOUS RATS [J].
DALY, DA ;
MOGHADDAM, B .
NEUROSCIENCE LETTERS, 1993, 152 (1-2) :61-64
[68]   Which characteristics of schizophrenia predate psychosis? [J].
Davies, N ;
Russell, A ;
Jones, P ;
Murray, RM .
JOURNAL OF PSYCHIATRIC RESEARCH, 1998, 32 (3-4) :121-131
[69]   Genetic dissection of structural and functional components of synaptic plasticity .3. CREB is necessary for presynaptic functional plasticity [J].
Davis, GW ;
Schuster, CM ;
Goodman, CS .
NEURON, 1996, 17 (04) :669-679
[70]   Molecular determinants of metabotropic glutamate receptor signaling [J].
De Blasi, A ;
Conn, PJ ;
Pin, JP ;
Nicoletti, F .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2001, 22 (03) :114-120